Drug Profile
OAS 403
Alternative Names: OAS403Latest Information Update: 16 Oct 2006
Price :
$50
*
At a glance
- Originator Genetic Therapy; Geron Corporation
- Class Oncolytic viruses
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 16 Oct 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 19 Jun 2003 Preclinical trials in Cancer in USA (unspecified route)
- 19 Jun 2003 Data presented at the 6th Annual Meeting of the American Society of Gene Therapy (ASGT-2003)have been added to the Cancer pharmacodynamics section